Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Rebecca Miksad

GI Oncology · BMC

View

Dr. Colin Weekes

GI Oncology · MGH

View

Dr. Elizabeth Jaffee

GI Oncology · Johns Hopkins

View

Dr. Aparna Parikh

GI Oncology · PHS

View

Dr. Laura Vater

GI Oncology · IUSM

View

Dr. Kathleen Cooney

GU Oncology · Duke

View

Dr. Rebecca Shatsky

Breast Oncology · UCSD

View

Dr. Robert Bast

Breast Oncology · MD Anderson Cancer Center

View

Dr. Julia Close

General Oncology · UF

View

Dr. Sara Tolaney

Breast Oncology · Dana-Farber Cancer Institute

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    NUDr. Nataliya Uboha

    Dr. Nataliya Uboha

    Medical Oncology · Gastrointestinal Oncology
    University of Wisconsin–Madison
    nataliya

    Research

    Current and Future Biomarkers in Esophagogastric Adenocarcinoma.

    2024

    Via Journal of Gastrointestinal Cancer

    Research

    Targeted Agents in Esophagogastric Cancer Beyond Human Epidermal Growth Factor Receptor-2.

    2024

    Via Hematology/Oncology Clinics of North America

    Research

    Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.

    2024

    Via Cancer Discovery

    Research

    Precision of liver and pancreas apparent diffusion coefficients using motion-compensated gradient waveforms in DWI.

    2024

    Via Magnetic Resonance Imaging

    Research

    Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.

    2024

    Via Clinical Cancer Research

    Research

    A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

    2024

    Via Clinical Cancer Research

    Research

    A phase II study of FOLFOX combined with nab-paclitaxel in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: a Big Ten Cancer Research Consortium trial.

    2024

    Via The Oncologist

    Research

    Treatment of Oligometastatic GI Cancers

    2024

    Via American Society of Clinical Oncology Educational Book

    Research

    Farnesoid X receptor mediates macrophage-intrinsic responses to suppress colitis-induced colon cancer progression

    2024

    Via JCI Insight

    Research

    Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline

    2023

    Via Journal of Clinical Oncology

    Research

    Undifferentiated Carcinoma of Esophagus with SMARCA4 Deletion Expressing Synaptophysin: A Potential Diagnostic Pitfall

    2023

    Via International Journal of Surgical Pathology

    Research

    Esophageal carcinoma with SMARCA4 mutation: Unique diagnostic challenges

    2023

    Via Pathology, Research and Practice

    Research

    NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma

    2023

    Via British Journal of Cancer

    Research

    Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

    2022

    Via The Lancet Oncology

    Research

    Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

    2022

    Via Clinical Cancer Research